UBS Group Cuts GoodRx (NASDAQ:GDRX) Price Target to $4.00

GoodRx (NASDAQ:GDRX) had its price target reduced by UBS Group from $4.25 to $4.00 in a report published on Thursday morning,Benzinga reports. UBS Group currently has a neutral rating on the stock.

Other analysts have also recently issued reports about the company. Mizuho lowered their target price on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $6.00 price objective on shares of GoodRx in a research report on Monday, August 11th. Weiss Ratings lowered shares of GoodRx from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Finally, Raymond James Financial lowered shares of GoodRx from a “strong-buy” rating to an “outperform” rating in a research note on Friday, August 8th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.58.

GoodRx Price Performance

GDRX opened at $3.11 on Thursday. The stock has a market cap of $1.08 billion, a P/E ratio of 34.56, a P/E/G ratio of 1.62 and a beta of 1.19. GoodRx has a 12 month low of $2.95 and a 12 month high of $5.81. The company has a quick ratio of 4.21, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The company has a fifty day simple moving average of $4.02 and a 200 day simple moving average of $4.28.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The business had revenue of $196.03 million during the quarter, compared to analyst estimates of $195.17 million. During the same period in the previous year, the firm posted $0.08 earnings per share. The firm’s revenue was up .4% on a year-over-year basis. GoodRx has set its FY 2025 guidance at EPS. On average, research analysts expect that GoodRx will post 0.13 EPS for the current year.

Insider Activity

In other news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $4.00, for a total value of $95,084.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 4.53% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the business. Citizens Financial Group Inc. RI bought a new stake in GoodRx during the 1st quarter worth about $44,000. Jump Financial LLC bought a new position in shares of GoodRx in the 1st quarter valued at about $49,000. Cetera Investment Advisers acquired a new stake in shares of GoodRx in the second quarter valued at about $50,000. Walled Lake Planning & Wealth Management LLC bought a new stake in GoodRx during the second quarter worth about $55,000. Finally, Tower Research Capital LLC TRC raised its holdings in GoodRx by 202.3% during the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock worth $56,000 after acquiring an additional 7,580 shares in the last quarter. Institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.